Celesio AG: Non-cash impairment on discontinued operations

Celesio AG  / Key word(s): Miscellaneous

08.05.2012 21:26

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Non-cash impairment on discontinued operations

During the course of compiling the financial statements for the quarter
ending 31 March 2012, Celesio conducted the necessary impairment tests to
calculate the value of discontinued operations as a result of the company's
strategic realignment. In doing so, it determined that the revaluation of
Pharmexx has now led to a non-cash impairment of 45 million EUR.

The management board assumes that the company will generate 2012 EBITDA
equal to or better than in the 2011 financial year, once adjusted for the
non-recurring effect of the Operational Excellence Programme. We are
expecting adjusted EBIT to follow a similar trend.

Based on the preliminary figures for the first quarter of 2012, Celesio
achieved revenues of around 5.64 billion EUR  (2011: 5.50 billion EUR ),
EBITDA adjusted for the non-recurring effect of the Operational Excellence
Programme of nearly 140 million EUR  (2011: 133 million EUR ) and EBIT
adjusted for the same item of around 107 million EUR  (2011: 103 million
EUR ). Consequently, the company was able to increase revenues and earnings
year-on-year based on comparable numbers.

The completed financial statements for the quarter ending 31 March 2012
will be published on 14 May 2012, as planned.


08.05.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Celesio AG
              Neckartalstr. 155
              70376 Stuttgart
              Germany
Phone:        +49 (0)711 5001-735
Fax:          +49 (0)711 5001-736
E-mail:       investor@celesio.com
Internet:     www.celesio.com
ISIN:         DE000CLS1001
WKN:          CLS100
Indices:      MDAX
Listed:       Regulierter Markt in Berlin, Düsseldorf, Frankfurt (Prime
              Standard), München, Stuttgart; Freiverkehr in Hamburg,
              Hannover; Terminbörse EUREX
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------